Marshall Fordyce's most recent trade in Vera Therapeutics Inc - Ordinary Shares - Class A was a trade of 16,925 Class A Common Stock done at an average price of $42.0 . Disclosure was reported to the exchange on Feb. 23, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 41.98 per share. | 23 Feb 2026 | 16,925 | 257,163 | - | 42.0 | 710,578 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2026 | 137,500 | 137,500 | - | - | Stock Option (right to buy) | |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2026 | 68,800 | 274,088 | - | 0 | Class A Common Stock | |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 27.89 per share. | 21 Feb 2025 | 10,613 | 213,740 | - | 27.9 | 296,032 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 27.55 per share. | 21 Feb 2025 | 7,975 | 205,765 | - | 27.6 | 219,732 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 28.32 per share. | 21 Feb 2025 | 1,100 | 204,665 | - | 28.3 | 31,150 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 161,500 | 161,500 | - | - | Stock Option (right to buy) | |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 80,750 | 224,353 | - | 0 | Class A Common Stock | |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2024 | 57,661 | 626,551 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 18 Dec 2024 | 57,661 | 143,603 | - | 2.9 | 167,032 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2024 | 15,625 | 686,087 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 18 Dec 2024 | 5,023 | 90,965 | - | 2.9 | 14,551 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Fordyce Marshall | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 43.52 per share. | 18 Dec 2024 | 5,023 | 85,942 | - | 43.5 | 218,609 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 44.03 per share. | 18 Dec 2024 | 4,635 | 85,942 | - | 44.0 | 204,094 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 18 Dec 2024 | 4,635 | 90,577 | - | 2.9 | 13,427 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 41.33 per share. | 18 Dec 2024 | 3,772 | 85,942 | - | 41.3 | 155,883 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Fordyce Marshall | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 18 Dec 2024 | 3,772 | 89,714 | - | 2.9 | 10,927 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Fordyce Marshall | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 42.35 per share. | 18 Dec 2024 | 2,195 | 85,942 | - | 42.3 | 92,949 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Fordyce Marshall | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 18 Dec 2024 | 2,195 | 88,137 | - | 2.9 | 6,358 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2024 | 1,875 | 684,212 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc (Class A) | Fordyce Marshall | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 18 Dec 2024 | 1,875 | 87,817 | - | 2.9 | 5,432 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Fordyce Marshall | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 43.81 per share. | 18 Dec 2024 | 1,875 | 85,942 | - | 43.8 | 82,144 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Fordyce Marshall | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2024 | 15,625 | 703,587 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 46.91 per share. | 11 Dec 2024 | 14,925 | 85,942 | - | 46.9 | 700,150 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Fordyce Marshall | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 11 Dec 2024 | 14,925 | 100,867 | - | 2.9 | 43,235 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2024 | 1,875 | 701,712 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 11 Dec 2024 | 1,775 | 87,717 | - | 2.9 | 5,142 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Fordyce Marshall | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 46.94 per share. | 11 Dec 2024 | 1,775 | 85,942 | - | 46.9 | 83,325 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 47.55 per share. | 11 Dec 2024 | 700 | 85,942 | - | 47.5 | 33,284 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 11 Dec 2024 | 700 | 86,642 | - | 2.9 | 2,028 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Fordyce Marshall | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 47.65 per share. | 11 Dec 2024 | 100 | 85,942 | - | 47.7 | 4,765 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Fordyce Marshall | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 11 Dec 2024 | 100 | 86,042 | - | 2.9 | 290 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Fordyce Marshall | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2024 | 15,625 | 722,962 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc (Class A) | Fordyce Marshall | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 48.18 per share. | 25 Nov 2024 | 7,665 | 85,942 | - | 48.2 | 369,330 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Fordyce Marshall | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 25 Nov 2024 | 7,665 | 93,607 | - | 2.9 | 22,204 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 47.05 per share. | 25 Nov 2024 | 6,579 | 85,942 | - | 47.0 | 309,532 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Fordyce Marshall | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 25 Nov 2024 | 6,579 | 92,521 | - | 2.9 | 19,058 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 49.00 per share. | 25 Nov 2024 | 1,875 | 85,942 | - | 49 | 91,875 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 48.76 per share. | 25 Nov 2024 | 1,875 | 85,942 | - | 48.8 | 91,425 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Fordyce Marshall | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 25 Nov 2024 | 1,875 | 87,817 | - | 2.9 | 5,432 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2024 | 1,875 | 721,087 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2024 | 1,875 | 719,212 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 25 Nov 2024 | 1,875 | 87,817 | - | 2.9 | 5,432 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 25 Nov 2024 | 1,381 | 87,323 | - | 2.9 | 4,000 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Fordyce Marshall | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 48.80 per share. | 25 Nov 2024 | 1,381 | 85,942 | - | 48.8 | 67,399 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2024 | 15,625 | 753,587 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 13 Nov 2024 | 12,218 | 98,160 | - | 2.9 | 35,393 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 49.54 per share. | 13 Nov 2024 | 12,218 | 85,942 | - | 49.5 | 605,314 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2024 | 7,500 | 738,587 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 49.00 per share. | 13 Nov 2024 | 7,500 | 85,942 | - | 49 | 367,500 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 13 Nov 2024 | 7,500 | 93,442 | - | 2.9 | 21,726 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 50.28 per share. | 13 Nov 2024 | 3,307 | 85,942 | - | 50.3 | 166,281 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 13 Nov 2024 | 3,307 | 89,249 | - | 2.9 | 9,580 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2024 | 1,875 | 747,962 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2024 | 1,875 | 749,837 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2024 | 1,875 | 746,087 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2024 | 1,875 | 751,712 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 49.50 per share. | 13 Nov 2024 | 1,875 | 85,942 | - | 49.5 | 92,811 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 13 Nov 2024 | 1,875 | 87,817 | - | 2.9 | 5,432 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 49.52 per share. | 13 Nov 2024 | 1,875 | 85,942 | - | 49.5 | 92,849 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 13 Nov 2024 | 1,875 | 87,817 | - | 2.9 | 5,432 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 49.57 per share. | 13 Nov 2024 | 1,875 | 85,942 | - | 49.6 | 92,951 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 13 Nov 2024 | 1,875 | 87,817 | - | 2.9 | 5,432 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 49.59 per share. | 13 Nov 2024 | 1,565 | 85,942 | - | 49.6 | 77,603 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 13 Nov 2024 | 1,565 | 87,507 | - | 2.9 | 4,533 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 50.35 per share. | 13 Nov 2024 | 310 | 85,942 | - | 50.4 | 15,609 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 13 Nov 2024 | 310 | 86,252 | - | 2.9 | 898 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 51.20 per share. | 13 Nov 2024 | 100 | 85,942 | - | 51.2 | 5,120 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 13 Nov 2024 | 100 | 86,042 | - | 2.9 | 290 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Oct 2024 | 15,625 | 772,962 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 39.81 per share. | 23 Oct 2024 | 12,715 | 307,972 | - | 39.8 | 506,121 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 23 Oct 2024 | 12,715 | 320,687 | - | 2.9 | 36,833 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 42.00 per share. | 23 Oct 2024 | 3,750 | 307,972 | - | 42 | 157,500 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 23 Oct 2024 | 3,750 | 311,722 | - | 2.9 | 10,863 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 40.70 per share. | 23 Oct 2024 | 2,310 | 307,972 | - | 40.7 | 94,022 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 23 Oct 2024 | 2,310 | 310,282 | - | 2.9 | 6,692 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Oct 2024 | 1,875 | 769,212 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Oct 2024 | 1,875 | 771,087 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 41.61 per share. | 23 Oct 2024 | 600 | 307,972 | - | 41.6 | 24,968 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 23 Oct 2024 | 600 | 308,572 | - | 2.9 | 1,738 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Oct 2024 | 15,625 | 788,587 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 38.08 per share. | 09 Oct 2024 | 12,273 | 307,972 | - | 38.1 | 467,406 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 09 Oct 2024 | 12,273 | 320,245 | - | 2.9 | 35,552 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 09 Oct 2024 | 3,352 | 311,324 | - | 2.9 | 9,710 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 38.83 per share. | 09 Oct 2024 | 3,352 | 307,972 | - | 38.8 | 130,162 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Sep 2024 | 15,625 | 811,712 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 45.42 per share. | 25 Sep 2024 | 8,643 | 307,972 | - | 45.4 | 392,608 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 25 Sep 2024 | 8,643 | 316,615 | - | 2.9 | 25,037 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 46.62 per share. | 25 Sep 2024 | 4,817 | 307,972 | - | 46.6 | 224,588 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 25 Sep 2024 | 4,817 | 312,789 | - | 2.9 | 13,954 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 47.06 per share. | 25 Sep 2024 | 2,165 | 307,972 | - | 47.1 | 101,883 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 25 Sep 2024 | 2,165 | 310,137 | - | 2.9 | 6,272 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Sep 2024 | 1,875 | 804,212 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Sep 2024 | 1,875 | 806,087 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Sep 2024 | 1,875 | 807,962 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Sep 2024 | 1,875 | 809,837 | - | - | Stock Option (Right to Buy) | |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 45.44 per share. | 25 Sep 2024 | 975 | 307,972 | - | 45.4 | 44,301 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 25 Sep 2024 | 975 | 308,947 | - | 2.9 | 2,824 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 45.48 per share. | 25 Sep 2024 | 975 | 307,972 | - | 45.5 | 44,341 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 25 Sep 2024 | 975 | 308,947 | - | 2.9 | 2,824 | Class A Common Stock |
| Vera Therapeutics Inc (Class A) | Marshall Fordyce | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 45.43 per share. | 25 Sep 2024 | 975 | 307,972 | - | 45.4 | 44,292 | Class A Common Stock |